Prescriptive contraceptive use among isotretinoin users in the Netherlands in comparison with non-users: A drug utilisation study

Pharmacoepidemiology and Drug Safety

Volumn 21, Issue 10, 2012, Pages 1060-1066

  Crijns, Hubertina J M J ^a,b   van Rein, Nienke ^a   Gispen de Wied, Christine C ^b   Straus, Sabine M ^b,c   de Jong van den Berg, Lolkje T W ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b MEDICINES EVALUATION BOARD   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Contraception; Isotretinoin; PPP adherence

Indexed keywords

CONTRACEPTIVE AGENT; ISOTRETINOIN; TERATOGENIC AGENT;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; CONTRACEPTION; DATA BASE; DRUG UTILIZATION; FEMALE; GENERAL PRACTITIONER; HUMAN; MAJOR CLINICAL STUDY; MEDICAL SPECIALIST; NETHERLANDS; PATIENT COMPLIANCE; PREGNANCY; PRESCRIPTION; PRIORITY JOURNAL; TERATOGENICITY;

ABNORMALITIES, DRUG-INDUCED; ADOLESCENT; ADULT; AGE DISTRIBUTION; CONTRACEPTIVE AGENTS; DERMATOLOGIC AGENTS; FEMALE; HUMANS; ISOTRETINOIN; MALE; MIDDLE AGED; NETHERLANDS; PRESCRIPTIONS;

EID: 84867143322     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3200     Document Type: Article

References (25)

1. Standard of Dutch College of General Practitioners: Acne.
2. Cunliffe WJ, Gould DJ. Prevalence of facial acne vulgaris in late adolescence and in adults. Br Med J 1979; 1: 1109-1110.
3. Schäfer T, Nienhaus A, Vieluf D, et al. Epidemiology of acne in the general population: the risk of smoking. Br J Dermatol 2001; 145: 100-104.
4. Nijsten T, Rombouts S, Lambert J. Acne is prevalent but use of its treatments is infrequent among adolescents from the general population. JEADV 2007; 21: 163-168.
5. Rosa F. Teratogenicity of isotretinoin. Lancet 1983; 322: 513.
6. Abroms L, Maibach E, Lyon-Daniel K, Feldman SR. What is the best approach to reducing birth defects associated with isotretinoin?. PLoS Med 2006 Nov; 3: 1978-1983.
7. www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Isotretinoin_29/WC500010882.pdf [assessed 17 March 2011].
8. Lammer E, Chen D, Hoar R, et al. Retinoic Acid Embryopathy. NEJM 1985; 313: 837-841.
9. Volume 9A of the Rules Governing Medicinal Products in the European Union - Guidelines on Pharmacovigilance for Medicinal Products for Human Use. Eudralex, version September 2008.
10. Autret-Leca E, Kreft-Jais C, Elefant E, et al. Isotretinoin exposure during pregnancy - Assessment of spontaneous reports in France. Drug Saf 2010; 33: 659-665.
11. Shin J, Cheetham T, Wong L, et al. The impact of the iPLEDGE program on isotretinoin fetal exposure in an integrated health care system. J Am Acad Dermatol 2011; 65: 1117-1125.
12. www.iadb.nl [assessed 17 March 2011].
13. www.whocc.no/atc [assessed 15 August 2010].
14. Vegter S, Kölling P, Töben M, et al. Replacing hormone therapy-is the decline in prescribing sustained, and are nonhormonal drugs substituted? Menopause 2009; 16: 329-335.
15. Tobi H, van den Berg PB, de Jong-van den Berg LTW. The interaction database: synergy of science and practice in pharmacy. In: Brause RW, Hanisch E, (eds) Medical data analysis. Springer: Berlin Heidelberg New York, 2000; pp 206-211.
16. Egede LE, Gebregziabher M, Hunt KJ, et al. Regional, geographic and ethnic differences in medication adherence among adults with Type 2 Diabetes. Ann Pharmacother 2011; 45: 169-178.
17. Aubeny E, Buhler M, Colau J-C, et al. Oral contraception: patterns of non-compliance. The Coraliance study. Eur J Contracept Reprod Health Care 2002; 7: 155-161.
18. www.z-index.nl [assessed 15 August 2010].
19. Autret-Leca E, Jonville-Béra A-P, Szafir D, et al. Roaccutane chez la femme en âge de procréer: étude de l'impact du renforcement des recommandations de prescription. Ann Dermatol Venereol 2000; 127: 808-813.
20. Kertzman MGM, Smeets JGE, Boukes FS, Goudswaard AN. Samenvatting van de standaard 'Acne' (tweede herziening) van het Nederlands Huisartsen Genootschap. Ned Tijdschr Geneeskd 2008; 152: 1271-1275.
21. Summary of Product Characteristics of Diane-35®. http://db.cbg-meb.nl/IB-teksten/h11903.pdf [assessed 6 September 2011].
22. Seaman HE, de Vries CS, Farmer RD. Differences in the use of combined oral contraceptives amongst women with and without acne. Hum Reprod 2003; 18: 515-521.
23. www.statline.cbs.nl [assessed 25 June 2010].
24. Teichert M, Visser L, Dufour M, et al. Isotretinoin use and compliance with the Dutch Pregnancy Prevention Programme A retrospective cohort study in females of reproductive age using pharmacy dispensing data. Drug Saf 2010; 33: 315-326.
25. Sundby J, Swanemyr J, Mæhre T. Avoiding unwanted pregnancy - the role of communication, information and knowledge in the use of contraception among young Norwegian women. Patient Educ Couns 1999; 38: 11-19.